

Consumer & Retail
Food Products
Equity – China

China Mengniu Dairy (2319 HK)

Buy

| | |
|---------------------|-------|
| Target price (HKD) | 48.00 |
| Share price (HKD) | 44.75 |
| Upside/Downside (%) | 7.3 |

| Performance | 1M | 3M | 12M |
|---------------------------|-----|------|------|
| Absolute (%) | 4.3 | 26.4 | 15.5 |
| Relative ^A (%) | 3.6 | 11.4 | -6.1 |

Index^A HANG SENG INDEX

RIC 2319.HK
Bloomberg 2319 HK

Market cap (USDm) 11,318
Market cap (HKDm) 87,745

Enterprise value (CNYm) 71637
Free float (%) 68

Buy Margin expansion likely to be intact

- ▶ **Mix improvement and lower raw milk price should remain the key drivers for margin expansion this year**
- ▶ **Compared with peers, Mengniu Dairy's operating margin is still low and we see potential for the company to further enhance its operational efficiency in the long run**
- ▶ **Reiterate Buy with an unchanged target price of HKD48.00**

Margin expansion likely to be intact: While Mengniu Dairy does not report quarterly financials, we believe it should have achieved a strong margin improvement in 1Q 2015 given that the average raw milk price in China has fallen 9% year-to-date and our recent store visits in Beijing and Shanghai also suggested that its higher-margin products like Milk Deluxe, Just Yogurt, and Yoyi C continued to outperform the low-end UHT and flavoured milk products. In addition, its peer Bright Dairy (600597 CH, RMB19.56, not rated), whose 1Q 2015 results were released in April-2015, also improved its net margin by 0.4ppt in the first quarter, which we believe is a positive read-across for Mengniu Dairy. In terms of sales by products, Milk Deluxe achieved high-teen sales growth in 2014 (16% of sales), and we expect it to grow by 8-9% this year. Just Yogurt had RMB900m sales in 2014, and we believe it could exceed RMB1,500m sales this year (3% of sales). Yoyi C revenue was up over 50% in 2014 (4% of sales), and we think it could achieve 30% growth this year, thanks to higher market share on the back of new product offering.

Room for further margin improvement: In addition to mix improvement and lower input cost, we believe there is still room for the company to expand its market share further and enhance its operational efficiency. Compared with the operating margin of its international peers like Danone, Mengniu Dairy's liquid milk margin is still 4-5ppt lower, and we believe there is potential for the company to further improve its operating margin through more stringent cost control and scale benefits, especially for the chilled yogurt business, which has a partnership with Danone. Danone's yogurt sales contributed around RMB200m revenue in 2014 due to consolidation in 2H 2014, and we expect the overall chilled yogurt business to account for 18% of total revenue in 2015e, up from 16% in 2014.

Earnings, valuation, and risks: Our earnings estimates for 2015-17e are 3-10% above consensus. Our target price of HKD48.0 is based on a sum-of-the-parts valuation and implies a 2015e PE of 26x, which is c8% higher than the historical average of 24x since January 2013. **Key downside risks:** 1) lower-than-expected sales volume due to a slowdown in dairy consumption or competition; 2) higher-than-expected raw milk costs; and 3) food safety risk.

27 May 2015

Christopher K Leung*

Analyst
The Hongkong and Shanghai Banking Corporation Limited
+852 2996 6531
christopher.k.leung@hsbc.com.hk

Erwan Rambourg*

Analyst
The Hongkong and Shanghai Banking Corporation Limited
+852 2996 6572
erwanrambourg@hsbc.com.hk

View HSBC Global Research at:
<http://www.research.hsbc.com>

*Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/qualified pursuant to FINRA regulations

Issuer of report: The Hongkong and Shanghai Banking Corporation Limited

Disclaimer & Disclosures

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it

Financials & valuation

Financial statements

| Year to | 12/2014a | 12/2015e | 12/2016e | 12/2017e |
|---|----------|----------|----------|----------|
| Profit & loss summary (CNYm) | | | | |
| Revenue | 50,049 | 55,644 | 62,672 | 70,010 |
| EBITDA | 4,006 | 4,595 | 5,624 | 6,227 |
| Depreciation & amortisation | -1,342 | -1,238 | -1,294 | -1,356 |
| Operating profit/EBIT | 2,665 | 3,356 | 4,330 | 4,871 |
| Net interest | 208 | 284 | 317 | 453 |
| PBT | 3,150 | 3,957 | 4,982 | 5,665 |
| HSBC PBT | 3,150 | 3,957 | 4,982 | 5,665 |
| Taxation | -459 | -645 | -856 | -1,028 |
| Net profit | 2,351 | 2,855 | 3,605 | 4,042 |
| HSBC net profit | 2,351 | 2,855 | 3,605 | 4,042 |

Cash flow summary (CNYm)

| | | | | |
|---------------------------|--------|--------|--------|--------|
| Cash flow from operations | -3,632 | 4,286 | 4,709 | 5,152 |
| Capex | -2,813 | -2,900 | -2,900 | -2,900 |
| Cash flow from investment | -4,202 | -2,361 | -2,314 | -2,179 |
| Dividends | -548 | -714 | -901 | -1,011 |
| Change in net debt | 605 | -1,211 | -1,494 | -1,963 |
| FCF equity | -6,175 | 1,708 | 2,160 | 2,732 |

Balance sheet summary (CNYm)

| | | | | |
|-------------------------|--------|--------|--------|--------|
| Intangible fixed assets | 8,936 | 9,014 | 9,089 | 9,164 |
| Tangible fixed assets | 11,697 | 13,382 | 15,012 | 16,581 |
| Current assets | 20,333 | 21,627 | 23,771 | 26,454 |
| Cash & others | 4,650 | 5,861 | 7,354 | 9,317 |
| Total assets | 47,081 | 50,137 | 53,987 | 58,314 |
| Operating liabilities | 12,553 | 13,011 | 13,637 | 14,338 |
| Gross debt | 9,943 | 9,943 | 9,943 | 9,943 |
| Net debt | 5,293 | 4,082 | 2,589 | 626 |
| Shareholders funds | 21,489 | 23,630 | 26,334 | 29,366 |
| Invested capital | 23,764 | 25,152 | 26,883 | 28,547 |

Ratio, growth and per share analysis

| Year to | 12/2014a | 12/2015e | 12/2016e | 12/2017e |
|------------------------------|----------|----------|----------|----------|
| Y-o-y % change | | | | |
| Revenue | 15.4 | 11.2 | 12.6 | 11.7 |
| EBITDA | 30.5 | 14.7 | 22.4 | 10.7 |
| Operating profit | 43.9 | 26.0 | 29.0 | 12.5 |
| PBT | 42.9 | 25.6 | 25.9 | 13.7 |
| HSBC EPS | 36.7 | 20.8 | 26.3 | 12.1 |
| Ratios (%) | | | | |
| Revenue/IC (x) | 2.4 | 2.3 | 2.4 | 2.5 |
| ROIC | 10.9 | 11.5 | 13.8 | 14.4 |
| ROE | 12.8 | 12.7 | 14.4 | 14.5 |
| ROA | 6.8 | 7.4 | 8.5 | 8.8 |
| EBITDA margin | 8.0 | 8.3 | 9.0 | 8.9 |
| Operating profit margin | 5.3 | 6.0 | 6.9 | 7.0 |
| Net debt/equity | 21.6 | 15.1 | 8.5 | 1.8 |
| Net debt/EBITDA (x) | 1.3 | 0.9 | 0.5 | 0.1 |
| Per share data (CNY) | | | | |
| EPS reported (fully diluted) | 1.21 | 1.46 | 1.84 | 2.07 |
| HSBC EPS (fully diluted) | 1.21 | 1.46 | 1.84 | 2.07 |
| DPS | 0.28 | 0.36 | 0.46 | 0.52 |
| Book value | 11.03 | 12.07 | 13.45 | 15.00 |

Valuation data

| Year to | 12/2014a | 12/2015e | 12/2016e | 12/2017e |
|--------------------|----------|----------|----------|----------|
| EV/sales | 1.4 | 1.3 | 1.1 | 1.0 |
| EV/EBITDA | 18.1 | 15.6 | 12.6 | 11.1 |
| EV/IC | 3.0 | 2.8 | 2.6 | 2.4 |
| PE* | 29.7 | 24.5 | 19.4 | 17.3 |
| P/Book value | 3.2 | 3.0 | 2.7 | 2.4 |
| FCF yield (%) | -9.2 | 2.5 | 3.2 | 4.0 |
| Dividend yield (%) | 0.8 | 1.0 | 1.3 | 1.4 |

Note: * = Based on HSBC EPS (fully diluted)



Note: price at close of 26 May 2015

Valuation and risks

We use a sum-of-the-parts method to value Mengniu Dairy as it has two distinct main businesses – a liquid milk operation and an infant formula business through Yashili. For the company’s core liquid milk business (excluding Yashili), we use a three-stage DCF model:

- ▶ Stage one: an explicit period of three years (2015-17e) with a revenue CAGR of 12 % and a NOPLAT CAGR of 21%;
- ▶ Stage two: a semi-explicit period of seven years with a NOPLAT CAGR of 9%, driven by a 10% revenue CAGR and a steady EBIT margin of 6.7%; and
- ▶ Stage three: a terminal growth rate of 3%.

In our DCF model for the liquid milk business, we use a WACC of 7.7%, which is derived from a risk free rate of 3.5%, a market risk premium of 5.5% and a cost of debt of 5.0%. Our fair value for the liquid milk business is HKD44.5, implying a 24.6x 2015e PE and 19.3x 2016e PE.

For Yashili’s (1230 HK, HKD2.60, Hold) equity value, we value its effective stake based on our target price of HKD2.80 for Yashili, which is based on 1.5x 2015e PB. Adding the two, we arrive at a target price for Mengniu Dairy of HKD48.00, representing a 26.3x 2015e PE or 20.9x 2016e PE.

Key risks

Key downside risks: 1) lower-than-expected sales volume due to a slowdown in dairy demand or competition; 2) higher-than-expected raw milk and operating costs; 3) food safety risk; 4) weaker-than-expected Yashili operation; and 5) any earnings dilutive acquisitions or VC-type investment

Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), and/or strategist(s) who is(are) primarily responsible for this report, certifies(y) that the opinion(s) on the subject security(ies) or issuer(s) and/or any other views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Christopher Leung and Erwan Rambourg

Important disclosures

Equities: Stock ratings and basis for financial analysis

HSBC believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations and that investors utilise various disciplines and investment horizons when making investment decisions. Ratings should not be used or relied on in isolation as investment advice. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations and therefore investors should carefully read the definitions of the ratings used in each research report. Further, investors should carefully read the entire research report and not infer its contents from the rating because research reports contain more complete information concerning the analysts' views and the basis for the rating.

From 23rd March 2015 HSBC has assigned ratings on the following basis:

The target price is based on the analyst's assessment of the stock's actual current value, although we expect it to take six to 12 months for the market price to reflect this. When the target price is more than 20% above the current share price, the stock will be classified as a Buy; when it is between 5% and 20% above the current share price, the stock may be classified as a Buy or a Hold; when it is between 5% below and 5% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold or a Reduce; and when it is more than 20% below the current share price, the stock will be classified as a Reduce.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation or resumption of coverage, change in target price or estimates).

Upside/Downside is the percentage difference between the target price and the share price.

Prior to this date, HSBC's rating structure was applied on the following basis:

For each stock we set a required rate of return calculated from the cost of equity for that stock's domestic or, as appropriate, regional market established by our strategy team. The target price for a stock represented the value the analyst expected the stock to reach over our performance horizon. The performance horizon was 12 months. For a stock to be classified as Overweight, the potential return, which equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated, had to exceed the required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile*). Stocks between these bands were classified as Neutral.

*A stock was classified as volatile if its historical volatility had exceeded 40%, if the stock had been listed for less than 12 months (unless it was in an industry or sector where volatility is low) or if the analyst expected significant volatility. However, stocks which we did not consider volatile may in fact also have behaved in such a way. Historical volatility was defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility had to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.


Rating distribution for long-term investment opportunities

As of 27 May 2015, the distribution of all ratings published is as follows:

| | | |
|-------------|-----|--|
| Buy | 38% | (29% of these provided with Investment Banking Services) |
| Hold | 44% | (29% of these provided with Investment Banking Services) |
| Sell | 18% | (20% of these provided with Investment Banking Services) |

For the purposes of the distribution above the following mapping structure is used during the transition from the previous to current rating models: under our previous model, Overweight = Buy, Neutral = Hold and Underweight = Sell; under our current model Buy = Buy, Hold = Hold and Reduce = Sell. For rating definitions under both models, please see “Stock ratings and basis for financial analysis” above.

Share price and rating changes for long-term investment opportunities



| Recommendation & price target history | | |
|---------------------------------------|-----------------|------------------|
| From | To | Date |
| N/A | Underweight (V) | 03 October 2012 |
| Underweight (V) | Underweight | 28 May 2013 |
| Underweight | Restricted | 18 June 2013 |
| Restricted | Underweight | 19 November 2013 |
| Underweight | Overweight | 16 June 2014 |
| Overweight | Buy | 31 March 2015 |
| Target Price | Value | Date |
| Price 1 | 19.70 | 03 October 2012 |
| Price 2 | 19.40 | 03 January 2013 |
| Price 3 | 24.00 | 28 May 2013 |
| Price 4 | Restricted | 18 June 2013 |
| Price 5 | 31.30 | 19 November 2013 |
| Price 6 | 34.50 | 02 March 2014 |
| Price 7 | 46.50 | 16 June 2014 |
| Price 8 | 45.20 | 11 February 2015 |
| Price 9 | 48.00 | 31 March 2015 |

Source: HSBC

HSBC & Analyst disclosures

Disclosure checklist

| Company | Ticker | Recent price | Price Date | Disclosure |
|---------------------|---------|--------------|-------------|------------|
| CHINA MENGNIU DAIRY | 2319.HK | 44.75 | 26-May-2015 | 4, 6, 11 |

Source: HSBC

- 1 HSBC has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.
- 4 As of 30 April 2015 HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- 5 As of 31 March 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- 6 As of 31 March 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking securities-related services.
- 7 As of 31 March 2015, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.
- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- 10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.
- 11 At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments (including derivatives) of companies covered in HSBC Research on a principal or agency basis.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research.

Additional disclosures

- 1 This report is dated as at 27 May 2015.
- 2 All market data included in this report are dated as at close 26 May 2015, unless otherwise indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.

Disclaimer

** Legal entities as at 30 May 2014*

'UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Bank Canada, Toronto; HSBC Bank, Paris Branch; HSBC France; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Madrid, Milan, Stockholm, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Brasil SA – Banco Múltiplo; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch

Issuer of report

The Hongkong and Shanghai Banking Corporation Limited

Level 19, 1 Queen's Road Central
Hong Kong SAR

Telephone: +852 2843 9111

Fax: +852 2596 0200

Website: www.research.hsbc.com

This document has been issued by The Hongkong and Shanghai Banking Corporation Limited ("HSBC") in the conduct of its Hong Kong regulated business for the information of its institutional and professional investor (as defined by Securities and Future Ordinance (Chapter 571)) customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited is regulated by the Hong Kong Monetary Authority. All enquires by recipients in Hong Kong must be directed to your HSBC contact in Hong Kong. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Division of HSBC only and are subject to change without notice. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK this report may only be distributed to persons of a kind described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. The protections afforded by the UK regulatory regime are available only to those dealing with a representative of HSBC Bank plc in the UK. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR.

In Japan, this publication has been distributed by HSBC Securities (Japan) Limited. It may not be further distributed in whole or in part for any purpose. In Korea, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. HBAP SLS is regulated by the Financial Services Commission and the Financial Supervisory Service of Korea.

In Canada, this document has been distributed by HSBC Bank Canada and/or its affiliates. Where this document contains market updates/overviews, or similar materials (collectively deemed "Commentary" in Canada although other affiliate jurisdictions may term "Commentary" as either "macro-research" or "research"), the Commentary is not an offer to sell, or a solicitation of an offer to sell or subscribe for, any financial product or instrument (including, without limitation, any currencies, securities, commodities or other financial instruments).

© Copyright 2015, The Hongkong and Shanghai Banking Corporation Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of The Hongkong and Shanghai Banking Corporation Limited. MICA (P) 157/06/2014, MICA (P) 136/02/2015 and MICA (P) 041/01/2015